摘要
【目的】建立能反映肝癌肝移植特点的肝癌复发动物模型。【方法】选用Wistar大鼠,实验组大鼠给予肝移植术后常规联合免疫抑制方案(MP+CSA),对照组仅同法使用生理盐水,两组均接受经门静脉系统接种walker-256肿瘤细胞株手术,观察60d,死后剖腹探查取病理检查。【结果】实验组手术时间为(22.6±0.6)min,对照组为(22.1±0.7)min,两组间差异无统计学意义(P>0.05);实验组生存时间为(14.8±2.3)d,对照组为(40.9±5.3)d,两组间差异有统计学意义(P<0.05)。实验组大鼠体质量减轻量(53.5±2.6)g,较对照组体质量减轻量(34.6±5.8)g差异有统计学意义(P<0.05);实验组大鼠肿瘤复发率为95%(19/20),对照组为40%(8/20),实验组大鼠肿瘤的复发率明显高于对照组大鼠(P<0.05)。【结论】该模型能够有效模拟肝癌肝移植术后肿瘤复发的主要特征,可以作为研究肝癌肝移植术后肿瘤复发的理想大鼠模型。
[Objective ] To establish a new animal model for investigating the recrudescent mechanism after liver transplantation for hepatoeellular cancer. [Methods] The 40 wistar rats were chosen and randomly divided into 2 groups, immunosuppression group and control group. The walker-256 cell line was injected via portal venous in both groups. Immunosuppression group received the combined immunosuppression regime （MP＋CSA）. Control group was applied NS simultaneity. Pathologic anatomic characters of the livers were collected by exploratory laparotomy after death or 60 days after the above treatment in both groups. [ Results ] The operation time of immunosuppression group was （22.6±0.6） min, while control group （22.1±0.7） rain. No significant difference was found between them （P 〉0.05）. The weight loss in immunosuppression group was higher than control group, which was （53.5±2.6）g and （34.6±5.8）g respectively （P〈 0.05）. Survival time were （14.8±2.3） days in immunosuppression group, shorter than control group （40.9 ±5.3） days （P〈 0.05）. The percentage of recrudescence rate was 95% （19/20） in immunosuppression group, higher than control group, 40% （8/20） （P〈 0.05）. [Conclusion] This model is an optimal clinical model to mimic the natural recrudescence characters of hepatocellular carcinoma in human body after liver transplantation.
出处
《中山大学学报（医学科学版）》
CAS
CSCD
北大核心
2006年第6期640-643,共4页
Journal of Sun Yat-Sen University:Medical Sciences
基金
科技部973计划基金资助项目(2003CB515507)
广东省自然科学基金资助项目(04105344)
广东省科技基金资助项目(2005B30501005)
广州市科技计划基金资助项目(2005Z3-E0101)
关键词
模型
动物
肝癌
肝移植
复发
models
animal
hepatocellular carcinoma
liver transplantation
recrudescence
